Diabetic Retinopathy Clinical Trial
— ECLIPSEOfficial title:
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
Verified date | July 2019 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
Status | Completed |
Enrollment | 270 |
Est. completion date | January 8, 2016 |
Est. primary completion date | January 8, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Active choroidal neovascularization (CNV) - Active macular edema (ME) - Rubeosis iridis/neovascular glaucoma. - Proliferative diabetic retinopathy requiring vitrectomy. Exclusion Criteria: - wet Age-related macular degeneration - pathologic myopia - pseudoxanthoma elasticum - diabetic macular edema - retinal vein occlusion - < 18 years of age - History of hypersensitivity to ranibizumab - Use of any systemic anti-angiogenic drugs 3 months before inclusion - Women of child-bearing potential and Pregnant or nursing (lactating) women. - Active or suspected ocular infection |
Country | Name | City | State |
---|---|---|---|
France | Novartis Investigative Site | Amiens Cedex 1 | |
France | Novartis Investigative Site | Angers | |
France | Novartis Investigative Site | Bobigny cedex | Seine Saint Denis |
France | Novartis Investigative Site | Bordeaux | |
France | Novartis Investigative Site | Bordeaux | |
France | Novartis Investigative Site | Caen | |
France | Novartis Investigative Site | Creteil | |
France | Novartis Investigative Site | Ecully | |
France | Novartis Investigative Site | Grenoble | |
France | Novartis Investigative Site | Grenoble | |
France | Novartis Investigative Site | Lille | |
France | Novartis Investigative Site | Lyon | |
France | Novartis Investigative Site | Lyon Cedex 04 | |
France | Novartis Investigative Site | Mantes la jolie | |
France | Novartis Investigative Site | Marseille | |
France | Novartis Investigative Site | Marseille Cedex 8 | |
France | Novartis Investigative Site | Melun | |
France | Novartis Investigative Site | Montauban | |
France | Novartis Investigative Site | Montpellier | |
France | Novartis Investigative Site | Mulhouse cedex | |
France | Novartis Investigative Site | Nantes Cedex 1 | |
France | Novartis Investigative Site | Nice | |
France | Novartis Investigative Site | Paris | |
France | Novartis Investigative Site | Paris | |
France | Novartis Investigative Site | Paris | |
France | Novartis Investigative Site | Paris | |
France | Novartis Investigative Site | Paris cedex 10 | |
France | Novartis Investigative Site | Paris Cedex 19 | |
France | Novartis Investigative Site | Paris, Cedex 12 | |
France | Novartis Investigative Site | Poitiers | |
France | Novartis Investigative Site | Rouen | |
France | Novartis Investigative Site | Saint-Jean | |
France | Novartis Investigative Site | Saitnt Herblain | |
France | Novartis Investigative Site | St-Priest-en-Jarez | |
France | Novartis Investigative Site | Strasbourg Cedex | |
France | Novartis Investigative Site | Toulouse | |
France | Novartis Investigative Site | Tours | |
France | Novartis Investigative Site | Tours | |
France | Novartis Investigative Site | Vannes |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) for ocular and non-ocular events. Due to early termination, only descriptive analysis was conducted. | 24 months | |
Secondary | Change From Baseline Best Corrected Visual Acuity (BCVA) for Patients With Choroidal Neovascularization (CNV) and Macular Edema (ME) | BCVA change for diseases affecting the macular area either through CNV or ME. BCVA is tested using the ETDRS (Early Treatment Diabetic Retinopathy Study), the Snellen or Monoyer scales. The three scales are designed to measure visual acuity. ETDRS score is expressed in letter, Snellen and Monoyer score in fraction. BCVA assessment is presented in ETDRS after conversion if collected in Snellen or Monoyer. (Monoyer converted to Snellen = 2 x (Monoyer fraction) and Snellen converted to approximate ETDRS letters = 1x log(Snellen fraction). ETDRS letter score was transformed in logMAR unit for statistical analysis (- LogMAR = -(ETDRS-85)/50). The worse ETDRS letter score is 0 (logMAR 2.3) and the best ETDRS letter score is 100 (logMAR -0.3). | 3 months, 12 months | |
Secondary | Average Change of Neovascularization Extension for Patients With Neovascular Glaucoma | The extent of iris neovascularization was assessed by iris photography and graded using the "Teich and Walsh grading system". This grading system measures the number of quadrant at iris pupillary zone or iris ciliary zone where iris neovascularization (NV) is observed. Grade 0 = "No iris vascularization", Grade 1= Less than 2 quadrants of NV at iris pupillary zone, Grade 2 = More than 2 quadrants of NV at iris pupillary zone, Grade 3 =Grade 2 + less than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae; Grade 4 =More than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae) |
3 month, 12 month | |
Secondary | Proportion of Patient With Vitreous Cavity Hemorrhage Occurrence for Patient With Proliferative Retinopathy | Occurrence of postoperative vitreous cavity hemorrhage | 3 months, 12 month | |
Secondary | Mean Change From Baseline in Change in Central Retinal Thickness for Patients With CNV (Choroidal Neovascularization) and ME (Macular Edema)" | CRT in micrometers assessed by Optical Tomography (OCT) at each single study visit. A reduction is thickness indicates an improvement is the lesion area | 3 months, 12 month | |
Secondary | Proportion of Patients With Angiographic Leakage | Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 3. Also any decreases of angiographic leakage was counted between baseline and 3 month. | 3 months, 12 month | |
Secondary | Ranibizumab Injection | Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in 3 months of observation period | 3 months, 12 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03660384 -
Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy
|
N/A | |
Completed |
NCT03660345 -
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
|
Phase 3 | |
Completed |
NCT03660371 -
ILM Peeling in PDR Patients Undergoing PPV for VH
|
N/A | |
Completed |
NCT04905459 -
ARDA Software for the Detection of mtmDR
|
||
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT05022615 -
Comparing 3 Imaging Systems
|
||
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT03702374 -
Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy
|
Phase 3 | |
Completed |
NCT04009980 -
Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus.
|
N/A | |
Completed |
NCT02924311 -
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
|
||
Not yet recruiting |
NCT06257082 -
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
|
N/A | |
Not yet recruiting |
NCT05452993 -
Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography
|
N/A | |
Withdrawn |
NCT02812030 -
Aflibercept for Retinopathy in the Real World
|
N/A | |
Completed |
NCT02391558 -
Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography
|
N/A | |
Active, not recruiting |
NCT02353923 -
OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy
|
N/A | |
Active, not recruiting |
NCT02330042 -
OCT Biomarkers for Diabetic Retinopathy
|
||
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT01950663 -
RETeval Study for Diabetic Retinopathy
|
N/A |